TETRAct-HIB contains Act-HIB (Haemophilus influenzae type b polysaccharide conjugated with tetanus protein) and D.T.COQ/D.T.P. (Purified diphtheria toxoid, Purified tetanus toxoid and killed whole cell Bordetella pertussis). This tetravalent combination vaccine is indicated for the prevention of invasive Haemophilus influenzae, type b infections (meningitis, septicaemia, cellulitis, arthritis, epiglottitis, etc.), diphtheria, tetanus and pertussis. TETRAct-HIB does not protect against infections due to other types of Haemophilus influenzae nor against meningitis of other origins.
Primary vaccination over two months of age, 3 injections of a unit dose of vaccine (0.5 ml) at one or two months interval. Booster dose of 1 injection one year after the 3rd injection of the primary vaccination. TETRAact-HIB can be started at 6 weeks age in countries where pertussis represents a major risk for infants.
For latest IAP updates see revised immunization schedule.
Diptheria, tetanus, pertussis, hib, DTP
Convulsant or non-convulsant progressive encephalopathy (neurological disease), strong reaction occurring within 48 hours following a previous vaccination: fever above or equal to 40°C, persistent crying syndrome, febrile or non-febrile convulsion, hypotonus – hyporeactivity syndrome, hypersensitivity appearing after a previous vaccination against diphtheria, tetanus and pertussis and known allergy to any of the ingredients of the vaccine.